Reduced intensity stem cell transplantation for treatment of Class 3 Lucarelli severe thalassemia patients

American Journal of Hematology

Volumn 82, Issue 12, 2007, Pages 1095-1098

  Hongeng, Suradej ^a   Pakakasama, Samart ^a   Chuansumrit, Ampaiwan ^a   Sirachainan, Nongnuch ^a   Sura, Thanyachai ^a   Ungkanont, Artit ^a   Chuncharunee, Suporn ^a   Jootar, Saengsuree ^a   Issaragisil, Surapol ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; ESTROGEN; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; HYDROXYUREA; IMMUNOGLOBULIN; LEFLUNOMIDE; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THIOTEPA;

ADOLESCENT; ADULT; ARTICLE; BK VIRUS; CD34 SELECTION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; EPSTEIN BARR VIRUS; FEMALE; FEVER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HERPES ZOSTER; HUMAN; LOW DRUG DOSE; LYMPH NODE IRRADIATION; MALE; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RETINITIS; SCHOOL CHILD; SIBLING; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; THALASSEMIA; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; STEM CELL TRANSPLANTATION; THALASSEMIA; TRANSPLANTATION CONDITIONING;

EID: 36749007160     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21002     Document Type: Article

References (23)

1. Lucarelli G, Clift R. Marrow Transplantation in Thalassemia, 3rd ed. Malden, MA: Blackwell Scientific; 2004. p 1412.
2. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia. Biol Blood Marrow Transplant 2003;9:519-528.
3. Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005;35:171-177.
4. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant disease children. Lancet 2004;364:156-162.
5. Krishnamurti L, Wu CJ, Baker S, Wagner J. Stable donor engraftment following reduced intensity hematopoietic cell transplantation for sickle disease. Biol Blood Marrow Transplant 2006;12 (Suppl):39.
6. Williams JW, Javald B, Kadambi PV, et al. Leflunomide for polyoma virus type BK nephropathy. N Engl J Med 2005;352:1157-1158.
7. Heath JA, Mishra H, Mitchell S, Waters KD, Tiedemann K. Estrogen as treatment of hemorrhagic cystitis in children and adolescents undergoing bone marrow transplantation. Bone Marrow Transplant 2006;37:523-526.
8. Gaziev D, Polchi P, Lucarrlli G, et al. Second marrow transplant for graft failure in patients with thalassemia. Bone Marrow Transplant 1999;24:1299-1306.
9. Hongeng S, Chuansumrit A, Hathirat P, Rerkamnuaychoke B, Chaisiripoomkere W, Jootar S. Full chimerism in nonmyeloablative stem cell transplantation in a β-thalassemia major patient (class 3 Lucarelli). Bone Marrow Transplant 2002;30:409-410.
10. Hongeng S, Pakakasama S, Chaisiripoomkere W, Ungkanont A, Jootar S. Nonmyeloablative stem cell transplantation with a haploidentical donor in a class 3 Lucarelli severe thalassemia patient. Bone Marrow Transplant 2004;34:271-272.
11. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclopsphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2 incompatible transplant SCID mice. Blood 1994:83:2360-2367.
12. Chandy M, Balasubramanian P, Ramachanran SV, et al. Randomized trial of two different conditioning regimens for bone marrow in thalassemia-the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005;26:839-845.
13. Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004:104:1201-1203.
14. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risk of G-CSF administration, leukopheresis, and standard marrow harvest: Ethical and safety consideration for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006;46:422-433.
15. Pakakasama S, Hongeng S, Chaisiripoomkere W, Chuansumrit A. Sirachainan N, Jootar S. Allogeneic peripheral blood stem cell transplantation in children with homozygous β-thalassemia and severe β-thalassemia hemoglobin E disease. J Pediatr Hematol Oncol 2004;26:248-252.
16. Storb RF, Champlin R, Riddle R, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. Hematology Am Soc Hematol Educ Program 2001;375-391.
17. Bradly MB, Sattler RM, Raftopoulos H, et al. Correction of phenotype on thalassemia mouse model using a nonmyeloablative marrow transplantation regimen. Biol Blood Marrow Transplant 2002;8:453-461.
18. Lucarelli G, Giardini C, Angelucci E. Bone Marrow Transplantation in Thalassemia. Boston, MA: Kluwer Academic; 1997. pp 305-315.
19. Muretto P, Angelucci E, Del Fiasco S, Lucarelli G. Reversal features of hepatic haemosiderosis and haemochromatosis in thalassemia after bone marrow transplantation. Prog Clin Biol Res 1989;309:299-314.
20. Krishnamurti L, Blazar BR, Wagner JE. Bone marrow transplantation without myeloablation for sickle cell disease. New Engl J Med 2001;344: 68.
21. Hongeng S, Pakakasama S, Chuansumrit A, et al. Outcomes of transplantation with related-and unrelated-donor stem cells in children with severe thalassemia. Biol Blood Marrow Transplant 2006;12:683-687.
22. Boech M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-558.
23. Van Esser JW, Niesters HG, van der Holt B, et al. Prevention Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364-4369.